Compound ID | 3630
Class: Small molecule antibacterial agent
| Description: | Synthetic compound; developed with improved potency from an early screening hit (JNJ-7310); comparable efficacy to linezolid when used in combination with bedaquiline and pretomanid in mice infected with TB; highly selective to Mycobacterium tuberculosis PurF; rapidly metabolised (high clearance) in mice |
| Institute where first reported: | Janssen Global Public Health, LLC, Janssen Pharmaceutica NV, Antwerp, Belgium |
| Year first mentioned: | 2025 |
| Development status: | Experimental |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| Guide to Pharmacology: | JNJ-6640 |
| Citation: | https://www.nature.com/articles/s41586-025-09177-7 |